Unknown Author
January 23, 2026
Sidley Represents Crown Bioscience in Its Acquisition of Indivumed GmbH Business Unit
2 min
AI-made summary
- Sidley is advising Crown Bioscience on its acquisition of the IndivuServ business unit from Indivumed GmbH
- The deal includes a biobank with nearly one million samples and related clinical data, as well as a network of over 60 clinical divisions across the United States, Europe, and Asia
- The transaction, subject to customary closing conditions, is expected to be completed in April 2023
- The Sidley team comprises lawyers from multiple practice areas.
Sidley is representing Crown Bioscience in its acquisition of the IndivuServ business unit of Indivumed GmbH, which includes the acquisition of both a biobank comprised of almost one million samples with associated clinical data and an extensive network of more than 60 clinical divisions in the United States, Europe, and Asia. Subject to customary closing conditions, the transaction is expected to close in April 2023.
The Sidley team is being led by Björn Holland, Nicolai M. Schwarz-Gondek, and James Lu (M&A) and includes Feifei Bian, Jennifer Geng, Chloe Lustig, Laura Persin and Armin Mustafić (M&A); Olivier Goarnisson, Anna-Shari Melin, Carlo Felizardo, and Daniel Madani (Food, Drug and Medical Device); Joshua T. Hofheimer, Jean Qiu, Sabrina K. Glavota, and Francesca L. Sadler (Technology and Life Sciences Transactions); Sheri Porath Rockwell, Lauren Cuyvers, and Matthias Bruynseraede (Privacy and Cybersecurity); Patrick J. Harrison and Elizabeth Chen (Antitrust/Competition); Sven De Knop, Jen Fernandez, James Mendenhall, Justin R. Becker, Kayla M. Scott, and Alessandra Moroni (Global Arbitration, Trade and Advocacy); and Rachel D. Kleinberg, Jörg Fischer, and Jonathan M. Westreich (Tax).~~Sidley is representing Crown Bioscience in its acquisition of the IndivuServ business unit of Indivumed GmbH, which includes the acquisition of both a biobank comprised of almost one million samples with associated clinical data and an extensive network of more than 60 clinical divisions in the United States, Europe, and Asia. Subject to customary closing conditions, the transaction is expected to close in April 2023.
The Sidley team is being led by Björn Holland, Nicolai M. Schwarz-Gondek, and James Lu (M&A) and includes Feifei Bian, Jennifer Geng, Chloe Lustig, Laura Persin and Armin Mustafić (M&A); Olivier Goarnisson, Anna-Shari Melin, Carlo Felizardo, and Daniel Madani (Food, Drug and Medical Device); Joshua T. Hofheimer, Jean Qiu, Sabrina K. Glavota, and Francesca L. Sadler (Technology and Life Sciences Transactions); Sheri Porath Rockwell, Lauren Cuyvers, and Matthias Bruynseraede (Privacy and Cybersecurity); Patrick J. Harrison and Elizabeth Chen (Antitrust/Competition); Sven De Knop, Jen Fernandez, James Mendenhall, Justin R. Becker, Kayla M. Scott, and Alessandra Moroni (Global Arbitration, Trade and Advocacy); and Rachel D. Kleinberg, Jörg Fischer, and Jonathan M. Westreich (Tax).
Article Author
Unknown Author
The Sponsor